Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

N/A

4(66.7%)

Phase 3

2(33.3%)

6Total

N/A(4)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04651777Phase 3Active Not Recruiting

Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma

Role: lead

NCT07143747Not Yet Recruiting

PAXT: Pulmonary Imaging of Mild Asthma Using 129Xe MRI and Tc-99-Labeled-Carbon-Imaging (Tc99CImaging)

Role: lead

NCT03733535Not ApplicableActive Not Recruiting

Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI

Role: lead

NCT02351141Not ApplicableRecruiting

Structure and Function MRI of Asthma

Role: lead

NCT02279329Not ApplicableRecruiting

Longitudinal Study of Helium-3 and Xenon-129 Magnetic Resonance Imaging

Role: lead

NCT02263794Not ApplicableCompleted

Hyperpolarized Magnetic Resonance Imaging in Asthma Pre- and Post-Bronchial Thermoplasty

Role: lead

NCT04206761Phase 3Withdrawn

Investigating the Effects of QVM149 on MRI Ventilation Defects

Role: lead

All 7 trials loaded